GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-19.1411.830.000.00
Return on Assets-9.986.526.846.84
Return on Capital Employed7.1818.5029.5529.55
Return on Invested Capital3.4214.9029.3931.78
Margins
EBITDA Margin10.1217.6526.9227.04
Operating Margin5.1914.0023.5523.55
Incremental Operating Margin82.9858.28
Pretax Margin0.3110.5011.6914.28
Net Income Margin-12.147.868.0210.14
Net Income to Common Margin-12.717.860.008.44
FCF Margin-9.85-11.8412.2912.29
Additional
Effective Tax Rate5,116.7225.1631.3829.01
Dvd Payout Ratio-8.216.7310.36
Sustainable Growth Rate-20.7111.030.000.00
Incremental Operating Margin %82.9858.2824.01
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.